Literature DB >> 12188891

The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer.

M E O'Dwyer1, B J Druker.   

Abstract

The tyrosine kinase inhibitor STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of cancer. This review details the steps in the development of this agent and highlights why this drug has been so successful in the treatment of chronic myelogenous leukaemia. Future directions including the mechanisms and management of resistance and new therapeutic strategies are discussed. Finally, the literature supporting the use of STI571 in other malignancies, including solid tumors is briefly reviewed.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 12188891     DOI： 10.2174/1568009013334250

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN： 1568-0096            Impact factor:   3.428


  8 in total

1.  Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity.

Authors:  Lan Zhou; Naili An; Rex C Haydon; Qixin Zhou; Hongwei Cheng; Ying Peng; Wei Jiang; Hue H Luu; Pantila Vanichakarn; Jan Paul Szatkowski; Jae Yoon Park; Benjamin Breyer; Tong-Chuan He
Journal:  Cancer Lett       Date:  2003-04-25       Impact factor: 8.679

Review 2.  Molecular pathology of tumor metastasis III. Target array and combinatorial therapies.

Authors:  József Tímár; Andrea Ladányi; István Peták; András Jeney; László Kopper
Journal:  Pathol Oncol Res       Date:  2003-04-18       Impact factor: 3.201

3.  A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

Authors:  Kiranmai Gumireddy; Stacey J Baker; Stephen C Cosenza; Premila John; Anthony D Kang; Kimberly A Robell; M V Ramana Reddy; E Premkumar Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-27       Impact factor: 11.205

4.  Design and synthesis of Pictet-Spengler condensation products that exhibit oncogenic-RAS synthetic lethality and induce non-apoptotic cell death.

Authors:  Rachid Skouta; Miki Hayano; Kenichi Shimada; Brent R Stockwell
Journal:  Bioorg Med Chem Lett       Date:  2012-06-30       Impact factor: 2.823

5.  Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression.

Authors:  Ashwani K Sood; Rakhee Saxena; Jeff Groth; Mohamed M Desouki; Chalong Cheewakriangkrai; Kerry J Rodabaugh; Chitta S Kasyapa; Joseph Geradts
Journal:  Hum Pathol       Date:  2007-05-22       Impact factor: 3.466

Review 6.  Involvement of crk adapter proteins in regulation of lymphoid cell functions.

Authors:  Sigal Gelkop; Yael Babichev; Rachel Kalifa; Ami Tamir; Noah Isakov
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

7.  Biological Validation of Novel Polysubstituted Pyrazole Candidates with in Vitro Anticancer Activities.

Authors:  Hoda H Fahmy; Nagy M Khalifa; Magda M F Ismail; Hend M El-Sahrawy; Eman S Nossier
Journal:  Molecules       Date:  2016-02-26       Impact factor: 4.411

Review 8.  The p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target.

Authors:  Aaron S Borders; Lucia de Almeida; Linda J Van Eldik; D Martin Watterson
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.